Allergic contact dermatitis caused by efinaconazole: positive patch test reactions up to 0.1% pet.

We report a case of contact dermatitis caused by both efinaconazole, a topical triazole antifungal drug, and luliconazole, a topical imidazole antifungal drug. Positive patch test reactions were observed with efinaconazole and luliconazole. A patch test with lanoconazole also elicited a positive reaction. We hypothesized that structural similarity between luliconazole and lanoconazole led to cross-reaction, and that the dithiolane ring common to both drugs or the structure of the vinyl imidazole with a dithiolane ring could be the antigenic determinant.Since efinaconazole and luliconazole have no common structures, patients could be sensitized to both drugs separately. The antigenic determinant of efinaconazole is unknown. However, the chemical formula of ravuconazole, an oral triazole antifungal drug, is similar to that of efinaconazole. Clinicians should carefully consider potential cross-reactivity between these drugs.

show abstract

“…3), it was thought that sensitization to the drugs occurred separately. Oiso et al reported a positive patch test for unused luliconazole 5) .…”

Section: Discussionmentioning

confidence: 99%

Contact Dermatitis Caused by Efinaconazole and Luliconazole

et al. 2021

View full text Add to dashboard Cite

show abstract

“…55 There were three case reports of confirmed allergic contact dermatitis due to efinaconazole. [165][166][167]…”

Section: Safetymentioning

confidence: 99%

Antifungal Selection for the Treatment of Onychomycosis: Patient Considerations and Outcomes

Axler,

Lipner

2024

IDR

View full text Add to dashboard Cite

Onychomycosis, a common fungal nail infection, affects >20% of adults over age 60 and >50% of people over age 70. Onychomycosis may cause pain, psychosocial problems, and secondary infections, therefore meriting treatment. This review describes the range of treatment modalities, including FDA-approved systemic drugs and topical therapies. Additionally, new and emerging oral and topical therapies are discussed. We emphasize the importance of tailoring onychomycosis therapy to individual patient characteristics, comorbidities, preferences, extent of nail involvement, and fungal species, such that physicians may optimize treatment outcomes, patient satisfaction, and safety.

show abstract

Contact Allergy to Topical Drugs

Goossens¹,

Gonçalo²

2020

Contact Dermatitis

View full text Add to dashboard Cite

Allergic contact dermatitis caused by efinaconazole: positive patch test reactions up to 0.1% pet.

Cited by 9 publications

References 3 publications

Contact Dermatitis Caused by Efinaconazole and Luliconazole

Contact Dermatitis Caused by Efinaconazole and Luliconazole

Antifungal Selection for the Treatment of Onychomycosis: Patient Considerations and Outcomes

Contact Allergy to Topical Drugs

Contact Info

Product

Resources

About